By Tiana Cole | HGP Nightly News|
With 449 new HIV cases recorded in 2024, the Ministry of Health is moving to secure access to a breakthrough medication that experts say could dramatically reduce new infections in Guyana. Health Minister Dr. Frank Anthony has confirmed that government is working to acquire lenacapavir, a long-acting injectable drug that prevents HIV with just two doses per year.
“There’s a new drug on the market that we are working to see whether we’ll be able to get it, and that’s lenacapavir,” Dr. Anthony explained. “You take it, and for six months you don’t need anything else—you’re protected.”
HIGH COST, BUT PRICE EXPECTED TO DROP
The minister noted that lenacapavir is currently very costly, with treatment in the United States priced at approximately US$25,000 per year. However, he said the price is expected to decline once the drug’s patent expires within the next one to two years. Guyana, he added, plans to access the drug at a more affordable rate once its global cost drops.
“A lot of people have said this can be a game-changer in terms of HIV care,” Dr. Anthony said. “We are working with our partners to see how we can access that medication.”
Once the drug becomes available locally, the Ministry of Health intends to provide it free of cost to patients.
CHALLENGES: TESTING, TREATMENT, AND VIRAL SUPPRESSION
Dr. Anthony also highlighted ongoing challenges in the national HIV response. While many people know their HIV status, a significant number do not seek treatment—even though free medication and support services are available.
“There’s still a percentage we need to work on to make sure everybody who knows their status and is positive comes for treatment,” he emphasized. “Those who are on treatment—we want to ensure they are virally suppressed.”
PREP REMAINS AVAILABLE FOR THOSE AT RISK
To further reduce new infections, the minister encouraged persons engaged in high-risk lifestyles to access the ministry’s Pre-Exposure Prophylaxis (PrEP) program. PrEP is a preventive medication taken before potential exposure to HIV.
“If you have a relationship with someone who is HIV positive, using PrEP would prevent you from getting infected,” Dr. Anthony said.
The introduction of lenacapavir, combined with expanded PrEP services and improved engagement in treatment, is expected to significantly strengthen Guyana’s HIV prevention strategy in the coming years.
